Curative Biotechnology, Inc. (CUBT)
| Previous Close | 0.0242 |
| Open | 0.0221 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0221 - 0.0320 |
| 52 Week Range | 0.0051 - 0.0400 |
| Volume | |
| Avg. Volume | 213,013 |
| Market Cap | 15.038M |
| Beta (5Y Monthly) | 224.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Apr 19, 2024 - Apr 21, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to its Board of Directors of Dr. Theresa Heah. Dr. Heah is expected to join its Board of Directors immediately as an independent director. In addition to other Board duties Dr. Heah will serve on the newly created Cl
- GlobeNewswire
Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors
Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann. Dr. Liebmann is expected to join its Board of Directors as an indepe
GlobeNewswireCurative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions
Appoints Paul Michaels Co-CEO of Parent and CEO of Subsidiary Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset lic
